Who should have breast magnetic resonance imaging evaluation?
about
Modern breast cancer detection: a technological reviewBreast magnetic resonance imaging as a problem-solving modality in mammographic BI-RADS 3 lesionsComputer-aided detection in breast MRI: a systematic review and meta-analysis.Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.A Retrospective Study Evaluating the Impact of Preoperative Breast MRI on Surgical Decision-Making in Young Patients (≤50 Years) with Invasive Breast Cancer.Is there a role for magnetic resonance imaging in diagnosing palpable breast masses when mammogram and ultrasound are negative?Occult primary breast cancer at a comprehensive cancer center.The Role of MR Mammography in Differentiating Benign from Malignant in Suspicious Breast Masses.Significance of breast lesion descriptors in the ACR BI-RADS MRI lexicon.Geographic and temporal trends in the management of occult primary breast cancer: a systematic review and meta-analysis.Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.Molecular and functional imaging of breast cancer.The case against routine preoperative breast MRI.The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.Polymer film-nanoparticle composites as new multimodality, non-migrating breast biopsy markers.Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.Post-clip placement MRI following second-look US-guided core biopsy for suspicious lesions identified on breast MRI.Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors.Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
P2860
Q30484044-D0E7F2D7-50CC-420B-86F7-8AC0E8282FE8Q34256451-2726F9D5-1E38-4002-B29A-FFF114F1531DQ35082628-93C5833A-64F3-4B43-8DF6-AD4BEAAFA430Q35928203-3A311280-7DC7-41AF-81D3-DB09CA43EFB5Q36912360-87A55E4E-5593-4D21-97D1-8C2642FDDA11Q36973916-6FBA82E7-E9BF-4B44-8132-9B7FF174F669Q37315777-7E5152D6-10F2-4B02-8EFC-ED4CFF3395D3Q37353188-AA1496D3-9000-46C4-B1A5-B84EBE82601DQ37357319-2EFA5349-E304-4F39-ACED-D4FE45824867Q37579558-CB713385-5DDF-4821-8EE7-2352FE0A3D7EQ37734922-DB855A5C-5123-4EB8-9782-1DE9C2410635Q37776141-CBB57EF7-B4AC-4803-9DE6-1207BCB16109Q38087389-5D876DE3-734B-4BDC-9CB7-EB87502B005EQ38474934-1144C4E3-32AA-4D49-A439-A8F68A98FFD4Q40851799-82EAE147-BB94-4B68-9EF1-C894D3843BA4Q41437393-76CF4144-E719-4E06-9E4D-1E87D8891E59Q44491240-6B3F0E2E-0193-4BB2-9828-DA5FD91B6F52Q48158272-4878819E-6A52-4C80-BB6A-2277EAF6A9A4Q52974218-B33AE1A6-BBDD-46EE-B093-3AFAC3038A04Q53080309-3F36CB3C-088A-4479-8F0D-909C8FC95480
P2860
Who should have breast magnetic resonance imaging evaluation?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Who should have breast magnetic resonance imaging evaluation?
@en
Who should have breast magnetic resonance imaging evaluation?
@nl
type
label
Who should have breast magnetic resonance imaging evaluation?
@en
Who should have breast magnetic resonance imaging evaluation?
@nl
prefLabel
Who should have breast magnetic resonance imaging evaluation?
@en
Who should have breast magnetic resonance imaging evaluation?
@nl
P356
P1476
Who should have breast magnetic resonance imaging evaluation?
@en
P2093
Susan Orel
P304
P356
10.1200/JCO.2007.14.3594
P407
P577
2008-02-01T00:00:00Z